{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:34:35Z","timestamp":1790890475016,"version":"4.1.0"},"reference-count":66,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:p>Treatment of serious gram\u2010positive infections presents multiple challenges. Treatment often results in prolonged hospitalization for administration of intravenous antimicrobials and presents an inefficient use of hospital resources. Prolonged hospitalization is typically also unfavorable to patient preferences and potentially subjects patients to additional health care\u2010associated complications. Current strategies of transition to outpatient settings\u2014outpatient parenteral antimicrobial therapy and use of oral antibiotics\u2014often do not adequately serve vulnerable populations for whom there is often no alternative to inpatient therapy. Specifically, people who use drugs, those who cannot reliably adhere to unsupervised treatment (poor mental or physical health), people with complicating life circumstances (e.g., homelessness, incarceration, rural location), and those with inadequate health insurance remain hospitalized for weeks longer than persons without such conditions. We suspected that long\u2010acting lipoglycopeptides (laLGP), such as dalbavancin and oritavancin, may be useful in patient transitions to outpatient settings. Thus, we conducted a search of the peer\u2010reviewed literature using the PubMed, Google Scholar, and MEDLINE databases. Based on accumulating literature, it appears that laLGPs offer a reliable alternative therapeutic strategy that addresses many of the personal and systemic barriers to the traditional transitioning approaches. Current evidence also suggests that these agents may be cost\u2010effective from patient, payer, and hospital perspectives. Barriers to broader use of laLGPs include, among others, a relative lack of prospective data regarding efficacy in serious infections, a narrow United States Food and Drug Administration\u2013approved indication restricted to only acute bacterial skin and skin structure infections, and lack of reimbursement infrastructure for inpatient settings.<\/jats:p>","DOI":"10.1002\/phar.2389","type":"journal-article","created":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T11:39:23Z","timestamp":1585827563000},"page":"469-478","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Advantages of Outpatient Treatment with Long\u2010Acting Lipoglycopeptides for Serious Gram\u2010Positive Infections: A Review"],"prefix":"10.1002","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1746-7462","authenticated-orcid":false,"given":"Martin","family":"Krsak","sequence":"first","affiliation":[{"name":"Department of Medicine Division of Infectious Diseases University of Colorado Anschutz Medical Campus Aurora Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Morrisette","sequence":"additional","affiliation":[{"name":"Department of Pharmacy\u2010Infectious Diseases University of Colorado Hospital Aurora Colorado"},{"name":"Department of Clinical Pharmacy University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Aurora Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Pharmacy\u2010Infectious Diseases University of Colorado Hospital Aurora Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Molina","sequence":"additional","affiliation":[{"name":"Department of Pharmacy\u2010Infectious Diseases University of Colorado Hospital Aurora Colorado"},{"name":"Department of Clinical Pharmacy University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Aurora Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misha","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Medicine Division of Infectious Diseases University of Colorado Anschutz Medical Campus Aurora Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Damioli","sequence":"additional","affiliation":[{"name":"Department of Medicine Division of Infectious Diseases University of Colorado Anschutz Medical Campus Aurora Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Pisney","sequence":"additional","affiliation":[{"name":"Department of Medicine Division of Infectious Diseases University of Colorado Anschutz Medical Campus Aurora Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy\u2010Orthopedics University of Colorado Hospital Aurora Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Poeschla","sequence":"additional","affiliation":[{"name":"Department of Medicine Division of Infectious Diseases University of Colorado Anschutz Medical Campus Aurora Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,4,23]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy867"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.07.001"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02626-15"},{"key":"e_1_2_12_5_1","unstructured":"Manufacturer's highlights on prescribing information: Oritavancin.http:\/\/www.orbactiv.com\/pdfs\/orbactiv\u2010prescribing\u2010information.pdf. Accessed June 19 2019."},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-016-0103-4"},{"key":"e_1_2_12_7_1","unstructured":"Dalbavancin official prescribing information pamphlet.http:\/\/content.stockpr.com\/duratatherapeutics\/files\/docs\/Dalvance+APPROVED+USPI.PDF. Accessed September 25 2015."},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz363"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1808312"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1710926"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(17)30375-3"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268810000464"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2015.02.020"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6722a2"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu559"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1086\/651076"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268813001544"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis030"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2017.05.007"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2018.03.001"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1606157"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/jhm.2582"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.130029"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2015.302885a"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ750"},{"key":"e_1_2_12_26_1","unstructured":"DrozdEM HobanN.Impact on Medicare Expenditures From Expanding Coverage of Infusion Therapy of Anti\u2010Infective Drugs to the Home Setting.2014.http:\/\/www.nhia.org\/resource\/legislative\/documents\/AvalereFinalHomeInfusionReport.pdf. Accessed September 3 2019."},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04550-14"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy331"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1086\/427283"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2014.05.014"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy279"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-019-0329-6"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-017-0156-z"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv156"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2057"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz479"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00981-15"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2015.1078339"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz162"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz274"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2016.22.6.752"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-015-0365-8"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.11.014"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-5-43"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.11.008"},{"key":"e_1_2_12_46_1","unstructured":"The Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms \u201cDISARM\u201d Act of 2019.https:\/\/www.idsociety.org\/news\u2010\u2010publications\u2010new\/articles\/2019\/disarm\u2010act\u2010provides\u2010framework\u2010needed\u2010to\u2010spur\u2010antibiotic\u2010rd\u2010protect\u2010existing\u2010drugs\/. Accessed January 18 2020."},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-019-0247-0"},{"key":"e_1_2_12_48_1","doi-asserted-by":"crossref","first-page":"e01873","DOI":"10.1128\/AAC.01873-17","article-title":"Evaluation of oritavancin dosing strategies against vancomycin\u2010resistant Enterococcus faecium isolates with or without reduced susceptibility to daptomycin in an in vitro pharmacokinetic\/pharmacodynamic model","volume":"62","author":"Belley A","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw451"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-015-0081-5"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2015.01.017"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05098-14"},{"key":"e_1_2_12_53_1","unstructured":"Study to Evaluate the Safety Tolerability and Pharmacokinetics of a New Formulation of Oritavancin in Healthy Volunteers. ClinicalTrial.gov;https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02471690. Accessed October 15 2019."},{"key":"e_1_2_12_54_1","unstructured":"Relative Exposure and Safety Study of a New Formulation of Oritavancinin in ABSSSI Patients. ClinicalTrials.gov.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03873987. Accessed October 15 2019."},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.11.023"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0374-9"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy051"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00766-08"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-016-2845-z"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2018.03.008"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01251-16"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz479"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.7.2169-2172.2001"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.06.023"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2017.01.003"},{"issue":"429","key":"e_1_2_12_66_1","first-page":"e1","article-title":"Emergence of dalbavancin non\u2010susceptible, vancomycin\u2010intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line\u2010associated bloodstream infection with a dalbavancin and vancomycin\u2010containing regimen","volume":"24","author":"Werth BJ","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41426-018-0205-z"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.2389","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2389","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2389","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2389","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:04:40Z","timestamp":1761044680000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,23]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1002\/phar.2389"],"URL":"https:\/\/doi.org\/10.1002\/phar.2389","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,23]]},"assertion":[{"value":"2020-02-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}